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Abstract
Background: The goal of this study is to determine if Rhodiola Crenulata (RC) has protective effects on mice hearts
with severe sleep apnea model.
Methods: Sixty-four C57BL/6 J mice 5–6 months old were distributed into 4 groups i.e. Control group (21 % O2,
24 h per day, 8 weeks, n = 16); Hypoxia group (Hypoxia: 7 % O2 60 s, 20 % O2 alternating 60 s, 8 h per day, 8 weeks,
n = 16); Hypoxia + 90RC and Hypoxia + 270RC group (Hypoxia for 1st 4 weeks and hypoxia pretreated 90 mg/Kg
and 270 mg/Kg Rhodiola Crenulata by oral gavage per day for 2nd 4 weeks, each n = 16). Excised hearts from 4
groups of mice were analyzed for heart weight index changes using H&E staining, TUNEL-positive assays and Western
Blotting protein.
Results: Cardiac widely dispersed TUNEL-positive apoptotic cells in mice hearts were less in Hypoxia + RC90 and
Hypoxia + RC270 than those in Hypoxia. Compared with Hypoxia, the protein levels of Fas ligand, Fas death receptors,
Fas-Associated Death Domain (FADD), activated caspase 8, and activated caspase 3 (Fas dependent apoptotic
pathways) were decreased in Hypoxia + RC90, Hypoxia + RC270. The protein levels of Bad, Bax, t-Bid, activated caspase
9, activated caspase 3 (mitochondria dependent apoptotic pathway) were less in Hypoxia + RC90, Hypoxia + RC270
than those in hypoxia. The protein levels of Bcl2, Bcl-xL, p-Bad (Bcl2-realted anti-apoptotic pathway) and VEGF, p-PI3k,
p-AKT (VEGF-related pro-survival pathway) were higher in Hypoxia + RC90, Hypoxia + RC270 than those in hypoxia.
Conclusions: Our findings suggest that Rhodiola Crenulata have protective effects on chronic intermittent
hypoxia-induced cardiac widely dispersed apoptosis via Fas-dependent and mitochondria-dependent apoptotic
and VEGF-related pro-survival pathway.
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Introduction
Obstructive sleep apnea (OSA) is a sleep breathing dis-
order characterized by intermittent upper airway col-
lapse during sleep and leads to sleep fragmentation [1].
Obstructive sleep apnea is often associated with cardio-
vascular diseases including coronary artery diseases and
congestive heart failure [2, 3]. Noninvasive mechanical
ventilation therapy reduced left ventricular end systolic
and diastolic diameters, reduced the occurrence of car-
diovascular complications in coronary heart disease with
OSA [4]. Chronic intermittent hypoxia (CIH) showed
various long-term cardiovascular pathophysiologic out-
comes during sleep which are similar to OSA [1].
Chronic intermittent hypoxia was often used in animal
models to simulate the experiment of obstructive sleep
apnea [5, 6].
Rhodiola Crenulata, a species of Rhodiola, was often
applied to avoid altitude sickness [7, 8] and it have been
reported to decreased hypoxia-induced oxidative stress
[8, 9]. In general, Rhodiola increased stress resistance,
cardiopulmonary protection, and cardiovascular function
[7]. Rhodiola rosea, a species of Rhodiola, as an adapto-
gen, have effects of anti-fatigue, anti-stress, anti-hypoxic,
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anti-cancer, and antioxidant in cell cultures, animals, or
humans [10, 11]. Salidroside [2-(4-hydroxyphenyl)ethyl
beta-D-glucopyranoside], a chemical component of
Rhodiola Crenulata with phenylpropanoid glycoside was
regarded as an active ingredient of Rhodiola [12]. In gen-
eral, salidroside have been reported to protect cardiomyo-
cytes against cardiotoxicity [13], stimulate mitochondrial
biogenesis, protect endothelial dysfunction [14], enhance
stem cells [15], induce erythropoietin [16]. In our previous
study, salidroside showed protection through chronic inter-
mittent hypoxia-induced Fas-dependent and mitochondria-
dependent apoptotic pathways on mice hearts [5]. However,
the effect of Rhodiola Crenulata on cardiovascular health is
still unclear.
The apoptosis decreases cardiomyocytes in cardiomy-
opathies and shows also to be a predictor of cardiac dis-
eases or heart failure [17]. From our previous studies,
cardiac apoptosis were found in obesity [18, 19] smoking ex-
posure [20], and under long-term but not short-term inter-
mittent hypoxia [6, 21, 22]. The Fas receptor-dependent and
mitochondria-dependent apoptotic pathways are the two
major pathways triggering cardiac apoptosis [23]. The Fas
receptor-dependent apoptotic (Type I) pathway is a key
pathway triggering cardiac apoptosis [23]. The Fas binding
the Fas receptor [23–25], trailed by Fas-receptor oligomer-
isation results in the death-inducing signal complex, be-
gins with recruitment of the Fas-Associated Death
Domain (FADD) adaptor protein [23]. The FADD acti-
vates caspase 8, cleaves pro-caspase 3 and undergoes auto-
catalysis forming active caspase 3, an effector caspase of
apoptosis [24, 25].
The mitochondria-dependent (Type II) apoptotic path-
way begins with the apoptosis-regulating protein Bcl-2
family, including anti-apoptotic Bcl-2 and Bcl-xL as well
as pro-apoptotic Bad and Bax [23, 25, 26]. Pro-apoptotic
Bcl2 family augments cytochrome c release from mito-
chondria [23, 25, 27]. Cytochrome c release into cytosol
activates caspase-9, then caspase-3 completes the apop-
totic program [23, 25]. Additionally, t-Bid was considered
to be a key intracellular molecule signaling mediator from
Fas to mitochondrial pathway since activated caspase 8
can cleave Bid to t-Bid then release cytochrome c to
mitochondria-dependent apoptosis activity [23, 24]. In our
previous studies, 8-week chronic intermittent hypoxia ac-
tivated the Fas-dependent and mitochondria-dependent
apoptotic pathways and increased cardiac apoptosis in ro-
dent hearts [5, 6, 21, 22].
Vascular Endothelial Growth Factor (VEGF), a potent
angiogenesis angiogenic growth factor, promotes sur-
vival, reduces Endothelial Cells apoptosis and activates
PI3K/Akt signaling in human endothelial cells [28].
VEGF up-regulates pro-survival Akt/Bcl-2 signaling
pathways as a survival factor for protecting cardiomyo-
cyte against apoptosis [29]. Akt, as a key part in the
phosphatidylinositide 3-kinase (PI3K) pathway, a vital
spot regulatory kinase through pro-survival and protect-
ive effect in myocardium [30].
The effect of Rhodiola Crenulata on cardiac apoptosis
in severe sleep apnea i.e. under chronic intermittent
hypoxia is not understood. In the study, we investigate
whether Rhodiola Crenulata have protective effects on
mice heart with chronic intermittent hypoxia. We hypoth-
esized that Rhodiola Crenulata may prevent cardiac apop-
tosis via Fas-dependent and mitochondrial-dependent
anti-apoptotic pathways and VEGF-related pro-survival
pathways in chronic intermittent hypoxia.
Materials and Methods
Animal model
The study was performed on sixty-four 5–6 months old
C57BL/6 J mice were divided into four groups i.e. Control
group (21 % O2, 24 h per day, 8 weeks, n = 16); Hypoxia
group (Intermittent hypoxia: 7 % O2 60 s and alternating
20 % O2 60 s, 8 h per day, 8 weeks, n = 16); Hypoxia +
90RC and Hypoxia + 270RC group (Intermittent hypoxia
for 1st 4 weeks; Intermittent hypoxia pretreated 90 mg/Kg
and 270 mg/Kg Rhodiola Crenulata by oral gavage per day
for 2nd 4 weeks, each n = 16). After exposure with nor-
moxia or hypoxia and saline or RC, the hearts were ex-
cised and analyzed by heart weight index, H&E staining,
TUNEL-positive assays and Western Blotting. Ambient
temperature was kept at 25 °C and the animals were ex-
posed to an artificial 12-h light–dark cycle, the light
period which began at 7:00 am. Mice were provided with
standard laboratory meals (Lab Diet 5001; PMI Nutrition
International Inc., Brentwood, MO, USA) and water ad
libitum. Protocols were proved by the Institutional Animal
Care and Use Committee of China Medical University,
Taichung, Taiwan.
Rhodiola crenulata
Rhodiola Crenulata was provided by TCM Biotech Inter-
national Corp (Taiwan). The extraction process was as
follows: The raw material was analyzed and verified to
be free of organic toxins and heavy metals (Pb, Hg, Cd,
As, Cu) or below acceptable levels. The raw material
was ground and sifted with a 20 mesh screen. The grainy
powder was extracted and compressed then freeze dried
to reduce water content to less than 8 %. The material
was then ground to return to a powder form (water less
6 %). The powder was sifted then packaged in a sterile
aluminum bag.
Echocardiography
The trans-thoracic echocardiographic images of all mice
were obtained using Philips M2424A ultrasound systems
(Andover, MA) in anesthesia with 1 % isoflurane through
a nose cone. The M-mode echocardiographic inspection
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was executed applying a 6–15 MHz linear transducer
(15–6 L) through a parasternal long axis approach. The
left ventricular M-mode dimensions on the stage of the
papillary muscles contained inter-ventricular septum
(IVS), left ventricular internal end-diastolic dimensions
(LVIDd), left ventricular internal end-systolic dimensions
(LVIDs), posterior wall thicknesses (LVPW), and fractional
shortening (FS). FS% was calculated as a result of the
equation FS% = [(LVIDd-LVIDs)/LVIDd]/100.
Cardiac characteristics
The hearts of mice in the four groups were extracted
and cleaned with PBS. The weights of the left ventricles
and the whole heart were measured. Once weighting,
the 6 hearts of mice in each group were soaked in for-
malin and added analyzed by Hematoxylin-eosin, Mas-
son trichrome staining, DAPI staining and TUNEL
assay. The other 6 hearts of mice in each group were
cleaned, frozen, and added analyzed by Western Blot-
ting. Besides, right tibia lengths were measured using a
digital caliper and the left heart weight were weighed.
The whole heart weight (WHW) to body weight (BW)
ratio, the left ventricle weight (LVW) to body weight
(BW) ratio, the left ventricle weight (LVW) to the to the
whole heart weight (WHW) ratio, and the whole heart
weight to tibia length and the left ventricle weight to
tibia length ratio were determined for analysis.
Tissue extraction
The left ventricle samples of cardiac tissue extracts were
homogenized in a lysis buffer at a ratio of 100 mg tissue/
1 ml buffer for 1 min to obtain cardiac tissue extracts.
The homogenates were put on ice for 10 min then cen-
trifuged at 12,000 g for 40 min twice. The supernatant
was collected and stored at −70 °C.
Electrophoresis and Western Blot
Protein concentration of heart tissue extracts was verified
by the Bradford method (Bio-Rad Protein Assay, Hercules,
CA, USA). Protein samples (50 μg/lane) were divided on a
10 % SDS polyacrylamide gel electrophoresis (SDS-PAGE)
among a fixed voltage of 75 V. Electrophoresed proteins
were relocated to polyvinylidene difluoride (PVDF)
membrane (Millipore, Bedford, MA, 0.45 μm pore size)
through a transfer equipment (Bio-rad). PVDF mem-
branes were incubated in 5 % milk within TBS buffer.
Primary antibodies containing Fas receptor, FADD, Bcl-xL,
Bcl-2, Bax, t-Bid, caspase 8, caspase-9, caspase-3, p-Bad,
VEGF, p-PI3k (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), Bad (BD Biosciences, San Jose, California, USA),
p-Akt (Cell Signaling Technology, South San Francisco,
CA, USA) and α-tubulin (Neo Markers, Fremont, CA,
USA) were diluted to 1:500 into antibody binding buffer
overnight on 4 °C. The immunoblots were cleaned in
TBS buffer three times for 10 min then set in the 2nd anti-
body solution consisting of donkey anti goat IgG-HRP,
goat anti-mouse IgG-HRP or goat anti-rabbit IgG-HRP
(Santa Cruz) planned as one hour and diluted five hun-
dred fold in a TBS buffer. The immunoblotted proteins
were visualized applying an augmented chemilumines-
cence ECL western Blotting luminal Reagent (Santa Cruz,
CA, USA), also quantified using a Fujifilm LAS-3000
chemiluminescence detection system (Tokyo, Japan).
H&E staining, Masson trichrome staining, and TUNEL
The heart was extracted then soaked in formalin, then
dehydrated via graded alcohols, after that embedded in
paraffin wax. In heart samples, the 0.2-μm thick paraffin
sections were cut from paraffin-embedded tissue blocks.
The tissue samples were dewaxed using in xylene immersion,
and then rehydrated. For Hematoxylin-eosin staining (H&E
staining), the slices were dyed with hematoxylin and eosin.
For Masson Trichrome Staining, the slices were dyed with
Masson Trichrome. After lightly rinsing with water, the
slides were dehydrated through graded alcohols then
immersed in Xylene twice. Photomicrographs were ob-
tained by Zeiss Axiophot microscopes. The Terminal
Deoxynucleotide Transferase-mediated dUTP Nick End
Labeling (TUNEL) assay were studied with an apoptosis
detection kit (Roche Applied Science, Indianapolis, IN,
USA) and observed that TUNEL-positive nuclei (fragmen-
ted DNA) fluoresced bright green at 450–500 nm. The
mean number of TUNEL-positive cells were calculated for
5–6 individual fields x 2 slices x 3 regions of the left ven-
tricle (the upper, the middle, the lower) removed from 6
mice hearts within all groups. All data counts were exe-
cuted in two independent individuals within a blind study.
Statistical analysis
The weight index, protein levels and percentage of
TUNEL positive cells were compared with the Control,
the Hypoxia, the Hypoxia + RC90 and the Hypoxia +
RC270 groups by analysis of variance with pre-planned
contrast comparison. In every case P < 0.05 was consid-
ered significant.
Results
Body weight and cardiac characteristics
Body weight, whole heart weight, left ventricular weight
in the Hypoxia, the Hypoxia + RC90, and the Hypoxia +
RC270 groups were similar to the Control group
(Table 1). Whole heart weight (WHW), left ventricular
weight (LVW), whole heart weight normalized by tibia
length (WHW/Tibia), left ventricular weight normalized
by tibia length (LVW/Tibia) in the Hypoxia + RC90, and
the Hypoxia + RC270 groups were similar to the Control
group. Inter-ventricular septum at diastole (IVSd), left
ventricle posterior wall thicknesses (LVPW), left ventricle
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internal dimension at diastole (LVIDd), left ventricular in-
ternal end-systolic dimensions (LVIDs) in the Hypoxia,
the Hypoxia + RC90, and the Hypoxia + RC270 groups
were similar to the Control group (Table 1). Compared to
the Control Group, fractional shortening (FS %) was de-
creased by chronic intermittent hypoxia about 6.2 %.
Compared to the Hypoxia Group, the Fractional Shorten-
ing (FS %) was increased in the Hypoxia + RC90 group
(4.8 %) and Hypoxia + RC270 group (8.0 %), respectively.
Cardiac histopathological changes of left ventricle
To determine if there were changes in cardiac architec-
ture, a histopathological analysis of ventricular tissue
stained with hematoxylin and eosin was performed. We
viewed 400X magnified images and found that the
ventricular myocardium in the Control group showed
normal architecture and interstitial space. We found ab-
normal myocardial architecture and the increased inter-
stitial space in the Hypoxia group. These myocardial
architecture abnormalities in the Hypoxia + RC90, Hyp-
oxia + RC270 groups were less than those in the Hypoxia
group (Fig. 1a).
TUNEL-positive apoptotic cells of left ventricle
To analyze the apoptotic activity in cardiac tissues, the
apoptotic cells and total cells were measured by TUNEL
assay and DAPI staining respectively. Hypoxia groups
stained with TUNEL assay had the most TUNEL-
positive cardiac cells when compared to the Control
group, Hypoxia + RC90 or the Hypoxia + RC270 groups.
Decreases in the number of TUNEL-positive cardiac
cells were detected in the Hypoxia + RC90 and the Hyp-
oxia + RC270 groups compared with the Hypoxia group.
TUNEL-positive cells relative to DAPI-stained nuclei
cells in the hypoxia group about 4.1 % is higher than
those in the Hypoxia + RC90 and the Hypoxia + RC270
group both about 0.9 % (Fig. 1).
Upstream components of cardiac Fas receptor dependent
apoptotic pathways
To determine the upstream components of cardiac Fas
receptor dependent apoptotic signaling pathways in mice
with treatment of RC under chronic intermittent hyp-
oxia, protein levels of Fas receptor and FADD in the ex-
cised hearts of the Control, the Hypoxia, the Hypoxia +
RC90 and the Hypoxia + RC270 groups were examined
by Western blotting. Compared with the Control group,
Fas receptor and FADD were significantly increased in the
Hypoxia group (Fig. 2). Fas receptor and FADD in the
Hypoxia + RC90 and Hypoxia + RC270 groups were sig-
nificantly lower than those in the Hypoxia group (Fig. 2).
Upstream components of cardiac mitochondrial-dependent
apoptotic pathways
To evaluate the cardiac Bcl-2 family in mitochondria-
dependent apoptotic pathways in mice with chronic
intermittent hypoxia and treatment with RC, we ana-
lyzed the protein levels of the Bcl-2 family (Bcl-xL, Bcl-2,
Bax, Bad, p-Bad) in the excised hearts of the Control
group, the Hypoxia, the Hypoxia + RC90 and Hypoxia +
RC270 groups by Western Blotting. Mitochondrial related
anti-apoptotic protein of Bcl-xL, Bcl-2, p-Bad in the
Table 1 Heart weight and echocardiographic indices
Control Hypoxia + Saline Hypoxia + RC90 Hypoxia + RC270
Number of mice 8 8 8 8
Body weight (BW), g 21.56 ± 0.56 21.95 ± 1.32 21.79 ± 1.04 20.50 ± 1.44
Whole heart weight (WHW), g 0.108 ± 0.009 0.111 ± 0.007 0.109 ± 0.015 0.107 ± 0.008
Left ventricular weight (LVW), g 0.078 ± 0.009 0.077 ± 0.008 0.076 ± 0.015 0.078 ± 0.004
WHW/BW (x104) 48.28 ± 5.62 50.74 ± 4.77 50.04 ± 8.22 52.73 ± 3.07
LVW/BW (x104) 37.75 ± 4.43 32.65 ± 9.76 34.97 ± 8.26 38.83 ± 3.26
LVW/WHW 0.73 ± 0.08 0.64 ± 0.19 0.69 ± 0.06 0.74 ± 0.05
WHW/Tibia, g/mm (x104) 58.74 ± 4.28 56.85 ± 16.99 60.79 ± 8.3 59.66 ± 4.72
LVW/Tibia, g/mm (x104) 43.02 ± 4.95 39.60 ± 11.79 42.40 ± 8.48 43.81 ± 2.40
(IVSd), mm 0.75 ± 0.06 0.70 ± 0.04 0.72 ± 0.09 0.69 ± 0.04
(LVPWd), mm 0.77 ± 0.08 0.61 ± 0.09 0.64 ± 0.10 0.68 ± 0.09
(LVIDd), mm 3.74 ± 0.20 3.69 ± 0.30 3.94 ± 0.16 3.58 ± 0.31
(LVIDs), mm 2.45 ± 0.44 2.63 ± 0.33 2.62 ± 0.20 2.27 ± 0.32
Fractional Shortening (FS), % 34.80 ± 10.43 28.61 ± 7.05* 33.39 ± 4.29# 36.64 ± 5.47##
Values are Mean ± SD. WHW/BW whole heart weight normalized by body weight; LVW/BW left ventricular weight normalized by body weight; LVW/WHW left
ventricular weight normalized by whole heart weight; WHW/Tibia whole heart weight normalized by tibia length; LVW/Tibia left ventricular weight normalized by
tibia length; IVSd inter-ventricular septum at diastole; LVPWd left ventricular posterior wall thickness at diastole; LVIDd internal dimension at diastole of left
ventricle; LVIDs internal dimension at systole of left ventricle; FS: fractional shortening (LVIDd-LVIDs/LVIDd x100)
* P < 0.05, significant differences from the Control group. #P < 0.05, ##P < 0.01, significant differences from the Hypoxia group
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(A) Hematoxylin-eosin staining 
Control Hypoxia+saline Hypoxia+RC90 Hypoxia+RC270
 Masson trichrome staining 




Control Hypoxia+saline Hypoxia+RC90 Hypoxia+RC270 
DAPI assay 
Control Hypoxia+saline Hypoxia+RC90 Hypoxia+RC270
Fig. 1 (See legend on next page.)
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Hypoxia + RC90 and Hypoxia + RC270 groups were
higher than those in the Hypoxia group. Mitochondrial re-
lated pro-apoptotic proteins of Bax and Bad were much
higher in the Hypoxia group than the Control group as
well as the Hypoxia + RC90 and Hypoxia + RC270 groups
(Fig. 3). The protein level of pro-apoptotic t-Bid, a main
intracellular molecule signaling mediator from Fas to
mitochondrial pathway, in the Hypoxia + RC90 and
Hypoxia + RC270 groups were significantly lower than the
protein in the Hypoxia group (Fig. 3).
Downstream components of cardiac Fas and
mitochondrial dependent apoptosis
To realize the downstream components of cardiac Fas re-
ceptor (caspase 8 and 3) and mitochondrial (caspase 9 and
3) dependent apoptotic pathways, the caspase 8, 9 and 3
were measured by Western blotting in hearts excised from
the four experimental groups. Western blot analysis
showed that the protein products of activated caspase 8, 9,
and 3 were higher in the Hypoxia groups than the Control
group. The protein level of activated caspase 8, 9, and 3 in
the Hypoxia + RC90 and Hypoxia + RC270 groups were
much lower than in the Hypoxia group (Fig. 4).
Cardiac VEGF-related pro-survival pathway
To understand the VEGF-related pro-survival pathway
in mice with chronic intermittent hypoxia and treatment
with RC, the VEGF, p-PI3k, p-Akt were measured by
Western blotting in hearts excised from the four experi-
mental groups. Western blot analysis showed that the
protein products of VEGF, p-PI3k and p-Akt were higher
in the RC groups than the Control group (Fig. 5). The
Fig. 2 a The representative protein products of Fas receptor and Fas-associated death domain (FADD) extracted from the left ventricles of excised hearts
in the Control, the Hypoxia, the Hypoxia + RC90, and the Hypoxia + RC270 RC groups were measured by Western Blot analysis. b The bars represent the
relative protein quantification of Fas receptor and Fas-associated death domain (FADD) on the basis of α-tubulin, respectively, and indicates
Mean values ± SD (n = 6 in each group). **P < 0.01, ***P < 0.001, are the significant differences from the Control. ###P < 0.001, are the significant
differences from the Hypoxia group
(See figure on previous page.)
Fig. 1 a Representative histopathological analysis of cardiac sections from left ventricles in the Control, the Hypoxia, the Hypoxia + RC90, and the
Hypoxia + RC270 RC groups was performed with Hematoxylin and eosin (H&E) staining and Masson trichrome staining method. The images were
magnified by 400 times. b The Representative stained apoptotic cells of cardiac sections from left ventricles in the Control, the Hypoxia, the
Hypoxia + RC90, and the Hypoxia + RC270 RC groups were measured by TUNEL assay with dark background (upper panels, green spots) and
staining with DAPI (lower panels, blue spots). The images were magnified by 400 times. c Bars presents the percentage of TUNEL positive cells
relative to the total DAPI cells (n = 6 in each group). **P < 0.01, denotes significant differences from the Control group. ##P < 0.01 denotes
significant differences from the Hypoxia group
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protein levels of VEGF, p-PI3k and p-Akt in the Hyp-
oxia + RC90 and Hypoxia + RC270 groups were much
higher than those in the Hypoxia group (Fig. 5).
Discussion
Major findings
The summarized conclusions are (1) Rhodiola Crenu-
lata treatment improved chronic intermittent hypoxia-
decreased cardiac fractional shortening. (2) The activity of
the cardiac Fas receptor-dependent apoptotic pathway in
mice with chronic intermittent hypoxia was significantly
decreased with treatment of Rhodiola Crenulata, which
data is based on decreases in Fas, FADD, activated caspase
8, activated caspase 3 compared to the Hypoxia group. (3)
The activity of the cardiac mitochondrial-dependent apop-
totic pathway in mice with chronic intermittent hypoxia
was significantly decreased with treatment of Rhodiola
Crenulata, which is based on increases in anti-apoptotic
protein levels, Bcl-xL, Bcl-2 and p-Bad, as well as decreases
in pro-apoptotic protein levels, Bad, Bax, t-Bid, activated
caspase-9 and activated caspase 3. (4) The activity of the
cardiac VEGF-related pro-survival pathway in mice with
Fig 3 a The representative protein products of Bcl-xL, Bcl2, Bax, p-Bad, Bad and t-Bid extracted from the left ventricles of excised hearts in the
Control, the Hypoxia, the Hypoxia + RC90, and the Hypoxia + RC270 RC groups were measured by Western Blotting analysis. b The bars represent
the relative protein quantification of Bcl-xL, Bcl2, Bax, p-Bad, Bad and t-Bid on the basis of α-tubulin and indicates Mean values ± SD (n = 6 in each
group). *P < 0.05, **P < 0.01, ***P < 0.001, are the, significant differences from the Control. #P < 0.05, ##P < 0.01, ###P < 0.001are the significant
differences from the Hypoxia group
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chronic intermittent hypoxia was significantly increased
with treatment of Rhodiola Crenulata, which is based on
increased in pro-survival protein VEGF, p-PI3k and p-AKT
level compared to the Hypoxia group. After integrating
our findings with previous apoptotic theories, we propose
a hypothesized diagram in Fig. 6, which shows that Rho-
diola Crenulata treatment prevents chronic intermittent
hypoxia-induced cardiac Fas-dependent apoptotic path-
way (Fas, FADD, activated caspase 8, activated caspase 3),
prevents chronic intermittent hypoxia-induced cardiac
mitochondrial-dependent apoptotic pathway (t-Bid, Bad,
Bax, activated caspase-9, and activated caspase-3 as well
as decreased anti-apoptotic Bcl-xL, Bcl-2, p-Bad), and
enhance chronic intermittent hypoxia-induced cardiac
VEGF-related pro-survival pathway (VEGF, p-PI3k and p-
AKT) (Fig. 6).
Experimental design
In humans, Rhodiola Crenulata extract treatment of
800 mg daily for 7 days before ascent and 2 days during
mountaineering of Hehuan Mountain in Taiwan pre-
vented the headaches of Acute Mountain Sickness [31].
The dosage of Rhodiola Crenulata powder 100 mg/Kg and
500 mg/Kg, once daily for 4 weeks, ameliorate sucrose-
induced acute hyperglycemia by gavage in mice [32]. Our
current study of treatment with Rhodiola Crenulata in
Fig. 4 a The representative protein products of activated caspase 8, activated caspase 9, and activated caspase 3 extracted from the left ventricles of
excised hearts in the Control, the Hypoxia, the Hypoxia + RC90, and the Hypoxia + RC270 RC groups were measured by Western Blotting analysis. b The
bars represent the relative protein quantification of activated caspase 8, activated caspase 9, and activated caspase 3 on the basis of α-tubulin, respectively,
and indicates Mean values ± SD (n = 6 in each group). **P < 0.01, ***P < 0.001 are the significant differences from the Control. ##P < 0.01, ###P < 0.001, are
the significant differences from the Hypoxia group
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mice was designed as 90 mg/Kg and 270 mg/Kg by oral
gavage. Our study suggests that the current dosage did
protect chronic intermittent hypoxia-induced cardiac
widely dispersed apoptosis. The reasons why long-term
intermittent hypoxia was designed as 8 weeks were based
on our previous studies. Long-term intermittent hypoxia
planned for 8 weeks could cause abnormal myocardial
architecture and increased pro-apoptotic BNIP3 and Bad
proteins on rat’s hearts [21] as well as could induce car-
diac widely dispersed apoptosis [5, 22]. Therefore, our
study design of 8 weeks chronic intermittent hypoxia as
negative control group and Rhodiola Crenulata treated for
4 weeks was validated based on the current findings. Be-
sides, we should caution that any Rhodiola Crenulata-
induced anti-apoptotic effect in the present investigation
might be caused by various factors and cannot be isolated
to any specific mechanism, such as effects of salidroside,
effects of tyrosol, anti-oxidation, inhibiting free radicals,
enhancing stem cells, inducing erythropientin or other un-
clear factors.
Rhodiola Crenulata appeared to prevent chronic intermit-
tent hypoxia-induced abnormal myocardial architecture
and cardiac dysfunction. We suggest that Rhodiola
Crenulata treatment may prevent chronic intermittent
Fig. 5 a The representative protein products of activated enhance VEGF-related pro-survival pathway (VEGF, p-PI3k, p-AKT) cardiac pro-survival pathway
extracted from the left ventricles of excised hearts in the Control, the Hypoxia, the Hypoxia + RC90, and the Hypoxia + RC270 RC groups were measured
by Western Blotting analysis. b The bars represent the relative protein quantification of VEGF, p-PI3k, and p-AKT on the basis of α-tubulin, respectively,
and indicates Mean values ± SD (n = 6 in each group). **P < 0.01, ***P < 0.001 are the significant differences from the Control. ##P < 0.01, ###P < 0.001, are
the significant differences from the Hypoxia group
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hypoxia-induced abnormal myocardial architecture
and progression. Rhodiola (not Rhodiola Crenulata) in-
creases myocardial performance resulting in increased
cardiac output in STZ-induced diabetic rats [33].
Cardiac widely dispersed apoptosis TUNEL-positive
cells showed attenuation after treatment with Rhodiola
Crenulata. This paper shows the therapeutic benefit of
Rhodiola Crenulata treatment on chronic intermittent
hypoxia-induced cardiac apoptosis. Salidroside, active
ingredients of Rhodiola Crenulata, protected the cardio-
myocytes against cardiotoxicity [13]. Salidroside had
protective effects on cardiomyocytes necrosis [34]. In
our previous study, Salidroside protected chronic inter-
mittent hypoxia-induced cardiac apoptosis on mice
hearts [5].
In our study, Rhodiola Crenulata treatment was shown
significantly to prevent chronic intermittent hypoxia-
induced cardiac Fas receptor-dependent apoptosis as
determined by decreases in hypoxia-induced cardiac Fas
receptors, FADD, activated caspase-8 levels and activated
caspase-3 levels in mice. Our study suggests that Rhodiola
Crenulata treatment will prevent chronic intermittent
hypoxia-enhanced Fas-dependent and mitochondrial-
dependent apoptotic pathway. In our previous study,
salidroside treatment decreased chronic intermittent
hypoxia-induced cardiac Fas ligand, Fas death receptors,
FADD, activated caspase 8, and activated caspase 3 in
mice hearts [5].
Our study suggests that Rhodiola Crenulata treatment
prevented mitochondrial-dependent apoptotic pathway in
mice with chronic intermittent hypoxia as discovered with
increases anti-apoptotic Bcl2 family members (Bcl-xL, Bcl-
2, p-Bad) and decreases in Bax, Bad, activated caspase-9
levels and activated caspase-3 within chronic intermittent
hypoxia-induced cardiac apoptosis. Our study suggests that
Rhodiola Crenulata treatment will prevent chronic inter-
mittent hypoxia-enhanced the intracellular signaling medi-
ator Bid from the Fas pathway to the mitochondrial
pathway. Salidroside, protected the cardiomyocytes against
doxorubicin-induced cardiotoxicity by limiting unnecessary
oxidative stress and activating a Bcl2-mediated survival sig-
naling pathway, protecting cardiac dysfunction, and de-
creasing cardiomyocyte apoptosis [13].
Our study suggests that the protein levels of VEGF-
related pro-survival pathway (VEGF, p-PI3k, p-AKT)
were decreased after chronic intermittent hypoxia on
mice hearts as well as Rhodiola Crenulata prevented
chronic intermittent hypoxia-induced cardiac widely
Fig. 6 Our hypothesis that Rhodiola Crenulata suppressed chronic intermittent hypoxia-induced cardiac Fas-dependent, mitochondria-dependent
apoptotic pathways and enhanced chronic intermittent hypoxia-induced cardiac VEGF-related pro-survival pathway. The data is based on chronic
intermittent hypoxia increases in pro-apoptotic Fas, FADD, activated caspase 8, activated caspase 3 (left pathway, Fas-dependent apoptotic
pathway), and chronic intermittent hypoxia decreases anti-apoptotic Bcl-xL, Bcl-2, and p-Bad, increases t-Bid, Bad, Bax, activated caspase-9, and
activated caspase-3 (middle pathway, mitochondria-dependent apoptotic pathway), and chronic intermittent hypoxia increased pro-survival
protein VEGF, p-PI3k and p-AKT (right pathway, pro-survival VEGF-related pathway). Rhodiola Crenulata decreases chronic intermittent hypoxia-induced
cardiac Fas-dependent and mitochondrial-dependent apoptotic pathways, but increases chronic intermittent hypoxia-induced cardiac VEGF-related
pro-survival pathway. The upward arrows and downward arrows represent the respective increases and decreases
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dispersed apoptosis. Salidroside was found to drive effect-
ive antioxidant properties and protect cells from apoptosis
by the PI3K/Akt pathway [35]. In our previous study,
salidroside had cardiac protection through chronic inter-
mittent hypoxia-induced apoptosis [5]. In two studies, sali-
droside protected against hypoxia-induced cardiomyocytes
necrosis and apoptosis by increasing VEGF levels [36], as
well as increased Akt phosphorylation, cardiomyocytes
against injury by PI3K/Akt pathway and increased PI3K
antioxidant enzyme [37]. Salidroside and Tyrosol, two
isolated compounds of Rhodiola, prevented apoptosis in
H9c2 cells, reduced caspase-3 activity, reduced cytochrome
c release and showed the anti-apoptotic effect of the
combination of the two components was more beneficial
than that of salidroside and tyrosol independently [38].
Radix et Rhizoma Rhodiolae Kirilowii, a species of Rho-
diola, enhances myocardial angiogenesis by increasing
VEGF in rats with hypoxia [39]. Rhodiola Crenulata at
90 mg/Kg and 270 mg/Kg have protective effects on
chronic intermittent hypoxia-induced cardiac widely dis-
persed apoptosis via Fas-dependent and mitochondria-
dependent apoptotic pathway and VEGF-related pro-survival
pathway. In summary, our study suggests that Rhodiola
Crenulata treatment in mice with chronic intermittent
hypoxia prevents Fas-dependent and mitochondrial-
dependent apoptotic pathways and enhances VEGF-
related cardiac pro-survival pathway.
Hypothesized clinical application
This study showed that Rhodiola Crenulata treatment
protects from cardiac dysfunction, damage and widely
dispersed apoptosis under chronic intermittent hypoxia,
an animal model of severe sleep apnea. Chronic inter-
mittent hypoxia is regarded as one of the major compo-
nents of obstructive sleep apnea [40]. Since cardiac
tissues are not easily extracted from human hearts, the
preventive effects of Rhodiola Crenulata on cardiac
widely dispersed apoptosis in the animal study might
provide new therapeutic information to prevent cardiac
apoptosis in patients with severe Obstructive Sleep
Apnea or hypoxia. Since Rhodiola Crenulata treatment
could prevent cardiac damage after chronic intermittent
hypoxia, we might further hypothesized that Rhodiola
Crenulata might be applied to patients with severe sleep
apnea to prevent cardiac apoptosis or heart failure and
increase cardiac survival. Further clinical studies are re-
quired to clarify our clinical hypotheses.
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